Long‐Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52‐Week Extension Trial
Headache - United Kingdom
doi 10.1111/head.13682
Full Text
Open PDFAbstract
Available in full text
Categories
Date
January 1, 2020
Authors
Publisher
Wiley